文献速递淋巴瘤白血病

复发/难治性B细胞急性淋巴细胞白血病和弥漫大B细胞淋巴瘤患者接受替沙仑赛治疗后体内CAR转基因水平的评估

Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL.
PubMed 文献 · Blood Adv · 2025-01-01

本研究评估替沙仑赛治疗复发/难治性B细胞急性淋巴细胞白血病(B-ALL)和弥漫大B细胞淋巴瘤(DLBCL)患者体内CAR转基因水平与疗效的关系。在儿童/年轻成人B-ALL中,持续完全缓解和CD19阴性复发患者的最大CAR T细胞血药浓度高于CD19阳性复发患者;成人DLBCL中未观察到明确关联。B-ALL中B细胞恢复>6个月者维持良好缓解,但早期B细胞恢复因移植删失未能确认作为复发指标。

要点

  • B-ALL中持续完全缓解和CD19阴性复发患者的最大CAR T细胞血药浓度高于CD19阳性复发患者。
  • DLBCL中体内动力学与疗效无明显关联,复发时转基因水平范围宽。
  • B-ALL中B细胞恢复>6个月者CAR T细胞扩增高于早期B细胞恢复者,但未确定明确截断值。

核心结论

  • 血CAR转基因水平可能与长期缓解相关,但对复发缺乏稳健的预测潜力。
  • B-ALL中二代测序检测微小残留病似乎是预测复发的可靠生物标志物。

研究设计与样本

  • 研究评估替沙仑赛治疗复发/难治性B-ALL和DLBCL患者体内CAR转基因水平与缓解/复发的关系。
  • 采用定量聚合酶链反应检测外周血CAR转基因水平。

主要发现

  • 儿童/年轻成人B-ALL中,持续完全缓解和CD19阴性复发患者的最大CAR T细胞血药浓度高于CD19阳性复发患者。
  • 成人DLBCL中,体内动力学与疗效无明显关联,复发时转基因水平范围宽。
  • B-ALL中B细胞恢复持续>6个月的患者CAR T细胞扩增高于输注后<6个月早期B细胞恢复者,但未确定B细胞恢复相关扩增水平的明确截断值。
  • B-ALL中多数患者B细胞恢复>6个月维持良好缓解,但早期B细胞恢复因移植高删失未能确认作为复发潜在指标。
  • DLBCL中B细胞恢复与复发无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • B-ALL中早期B细胞恢复因移植高删失未能确认作为复发潜在指标。
  • B-ALL中未能确定B细胞恢复相关扩增水平的明确截断值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tisagenlecleucel is a CD19-directed autologous chimeric antigen receptor (CAR) T-cell therapy. Quantitative polymerase chain reaction assays are highly sensitive in defining in vivo kinetics by measuring CAR transgene in peripheral blood. This study aimed to identify clinically meaningful CAR T-cell blood levels that correlated with response/relapse. In pediatric/young adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), maximum CAR T-cell blood levels were higher in patients with ongoing complete remission and in patients with CD19- relapse relative to those with CD19+ relapse. In adult patients with R/R diffuse large B-cell lymphoma (DLBCL), no apparent association between in vivo kinetics and response was noted, with a wide range of transgene levels at relapse. In B-ALL, patients with B-cell aplasia sustained >6 months had higher CAR T-cell expansion relative to those with early B-cell recovery (BCR) (<6 months after infusion); however, a definitive cutoff for BCR-associated expansion level could not be identified. In most patients with B-ALL, BCR >6 months maintained favorable responses. However, early BCR could not be confirmed as a potential indicator of relapse due to high censoring from transplant, following presumed risk of relapse. However, allografting in these patients may potentially mitigate the poor prognosis related to early BCR. In DLBCL, BCR was not associated with relapse. These findings suggest that blood CAR transgene levels may be associated with long-term responses; however, they lack robust predictive potential for relapses. As reported earlier, next-generation sequencing for minimal residual disease appears to be a reliable biomarker predictive of relapse for B-ALL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Awasthi R, Grupp SA, Waldron ER, et al. Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL. Blood Adv. 2025. PMID: 40554413. doi:10.1182/bloodadvances.2024014995

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。